GSK Cervarix® two-dose schedule receives European marketing authorisation
GlaxoSmithKline (GSK) announced today that the European Commission has granted marketing authorisation for its cervical cancer vaccine Cervarix® [Human papillomavirus bivalent (types 16 and 18) vaccine, recombinant].
Source: GSK news - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Cervical Cancer | Cervical Cancer Vaccine | Genital Warts | Human Papillomavirus (HPV) | Marketing | Pharmaceuticals | Vaccines